News

Explore This Section

In Memoriam - Brian Roe

Brian Roe

In memoriam: Brian Roe, 41, director at UCLA Technology Development Group   

 

Marivi Valcourt | April 5, 2022

Brian Roe, director of the industry research and material transfer team at the UCLA Technology Development Group, died March 23.             He was 41. 

Potential glioblastoma treatment has roots in UCLA graduate research

Potential glioblastoma treatment has roots in UCLA graduate research

Recently approved for clinical trials, ERAS-801 was developed by a trio of faculty members

 

Marivi Valcourt | March 15, 2022

A potential new treatment for glioblastoma that recently received approval for clinical trials not only was developed by three UCLA faculty members but also traces its roots back to 2005, when one of the researchers was a UCLA graduate student.

UCLA Considers Underserved Populations When Licensing Medical Research Discoveries

UCLA Considers Underserved Populations When Licensing Medical Research Discoveries

UCLA is committed to its public-service mission of transparent and equitable biomedical research that enhances understanding of disease and leads to new treatments. Discoveries made in UCLA’s laboratories are available as medications worldwide.

Erasca Announces FDA Clearance of UCLA Developed Drug

UCLA Researchers David Nathanson, Ph.D., Michael Jung, Ph.D., and Timothy Cloughesy, M.D. developed ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM). The company Erasca licensed ERAS-801 from Katmai Pharmaceuticals, Inc. and received FDA clearance.